Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of firocoxib tablets in China. Welcome to wholesale bulk high quality firocoxib tablets for sale here from our factory. Good service and reasonable price are available.
The core active ingredient of Firocoxib Tablets is Firocoxib, with the chemical name 3- (cyclopropylmethoxy) -5,5-dimethyl-4- [4- (methylsulfonyl) phenyl] -2 (5H) - furanone. Its molecular formula is C17H20O5S, with a molecular weight accurate to 336.40 and a CAS number of 189954-96-9. The compound is in the form of white or off white crystalline powder, with a melting point range of 78-80 ° C, a predicted boiling point of 563.9 ± 50.0 ° C, and a density of 1.31g/cm ³. Its solubility characteristics are manifested as being soluble in chloroform, ethyl acetate, and methanol, but the solubility is limited, and the formulation process needs to be optimized through a specific solvent system. The cyclopropylmethoxy group, methylsulfonylphenyl group, and furanone ring in the chemical structure together form the active center for selective inhibition of COX-2 enzyme.
Ferocoxib tablets are supplied in the form of chewable tablets, with common specifications including 57mg and 227mg. This dosage form design significantly improves the convenience of administration, especially suitable for animals such as dogs that require long-term medication. Chewing tablets are processed through special techniques to rapidly disintegrate drugs in the oral cavity, reducing direct irritation to the gastrointestinal tract while increasing bioavailability.
Our product
Additional information of chemical compound:
| Product Name | Ketoconazole Tablets | Prilocaine Injection |
| Product Type | Tablets | Injection |
| Product Purity | HPLC≥99.0% | ≥99% |
| Product Specifications | Customizable | Customizable |
| Product Package | PE/Al foil bag/ paper box for Pure powder |
Customizable |
|
|
|
Ketoconazole+. COA
 |
||
Certificate of Analysis |
||
|
Compound name |
Ketoconazole | |
|
CAS No. |
65277-42-1 | |
|
Grade |
Pharmaceutical grade | |
|
Quantity |
Customized | |
|
Packaging standard |
Customized | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
|
Lot No. |
20250109001 |
|
|
MFG |
Jan 12th 2025 |
|
|
EXP |
Jan 8th 2029 |
|
|
Structure |
|
|
| TEST STANDARD | GB/T24768-2009 Industry. Stnndard | |
|
Item |
Enterprise standard |
Analysis result |
|
Appearance |
White or almost white powder |
Conformed |
|
Water content |
≤4.5% |
0.30% |
| Loss on drying |
≤1.0% |
0.15% |
|
Heavy Metals |
Pb≤0.5ppm |
N.D. |
|
As≤0.5ppm |
N.D. | |
|
Hg≤0.5ppm |
N.D. | |
|
Cd≤0.5ppm |
N.D. | |
|
Purity (HPLC) |
≥99.0% |
99.5% |
|
Single impurity |
<0.8% |
0.48% |
|
Residue on ignition |
<0.20% |
0.064% |
|
Total microbial count |
≤750cfu/g |
80 |
|
E. Coli |
≤2MPN/g |
N.D. |
|
Salmonella |
N.D. | N.D. |
|
Ethanol (by GC) |
≤5000ppm |
400ppm |
|
Storage |
Store in a sealed, dark and dry place at-20 degrees |
|
 |
||
 |
||
Pharmacological mechanism and target of action
Selective inhibition principle of COX-2
Ferocoxib is a selective inhibitor of COX-2, with an IC50 value of 0.13 μ M for COX-2 and 7.5 μ M for COX-1, with a selectivity ratio of up to 58 times. Based on the IC80 value calculation, the selectivity ratio was further increased to 121 times, indicating that at clinically effective concentrations, its inhibition rate of COX-1 was less than 20%. Ferocoxib exerts anti-inflammatory, analgesic, and antipyretic effects by specifically blocking the COX-2 enzyme in the arachidonic acid metabolism pathway, reducing the production of pro-inflammatory mediators such as prostaglandin E2 (PGE2).
Comparative advantages with traditional NSAIDs
Traditional nonsteroidal anti-inflammatory drugs (such as aspirin and ibuprofen) simultaneously inhibit COX-1 and COX-2, which can lead to side effects such as gastrointestinal mucosal damage and platelet dysfunction. Ferocoxib significantly reduces the risk of gastrointestinal ulcers by selectively inhibiting COX-2 and preserving COX-1-mediated functions such as gastrointestinal mucosal protection and platelet aggregation. In addition, the selective inhibition of COX-2 by fexorubicin also reduces the regulatory effect of prostaglandins on renal blood flow, reducing the risk of nephrotoxicity.
Pain Management in Dogs
Osteoarthritis: Firocoxib tablets are one of the preferred drugs for osteoarthritis such as hip dysplasia and elbow dysplasia in dogs. Clinical studies have shown that a dose of 5mg/kg/d can significantly reduce lameness scores, improve the mobility and quality of life of dogs. Long term medication can delay joint degeneration and reduce the need for joint replacement surgery.
Postoperative analgesia: It is recommended to administer fexorubicin tablets for the first time 2 hours before orthopedic or soft tissue surgery, and it can effectively control postoperative acute pain for 3 consecutive days. Its long-lasting analgesic effect reduces the use of postoperative opioid drugs, lowers the risk of respiratory depression and addiction.
Special scenario: Non Rocoxib tablets can also be used to treat dental surgery pain and inflammation caused by traumatic injuries in dogs. Its rapid onset and long-lasting effect make it an indispensable analgesic drug in veterinary clinical practice.
Pain Management in Horses
Equioxx, a non rocuronium drug preparation ®) Approved for relieving pain in equine osteoarthritis, with a dosage of 0.1mg/kg/d, taken orally. Horses have a slower metabolism rate of NSAIDs compared to dogs, making them prone to accumulation poisoning. Therefore, strict monitoring of blood drug concentration and liver and kidney function is necessary. The application of fipronil in horses has significantly improved the athletic performance of competitive horses and extended their lifespan.
Competitive horses: Used 24 hours before the race to reduce muscle inflammation caused by training, but must comply with the drug testing rules of the race.
Pharmacokinetic characteristics
Pharmacodynamics of Dogs
After oral administration of fericoxib chewable tablets to dogs, the average bioavailability is 38%, and the food can delay absorption without affecting the total amount. After a single administration, the peak blood concentration is reached 1-5 hours later, with an apparent distribution volume of 3L/kg and a plasma protein binding rate of 96%. The drug is mainly metabolized through liver dealkylation and glucuronidation, excreted through bile and feces, with a half-life of 6-8 hours. Long term medication requires monitoring of liver and kidney function to avoid drug accumulation.
Pharmacokinetic exploration of cats
Although fexorubicin tablets have not been approved for cat use, experimental studies have shown that oral suspension in cats increases bioavailability to 60% and prolongs half-life to 10 hours. This discovery suggests the potential application value of fexorubicin in pain management in cats, but further validation of its long-term safety and effectiveness is needed.
Dosage and administration plan
Standard Dose
Dogs: 5mg/kg, taken orally once daily. Can be taken with food to reduce stomach irritation, but high-fat diet should be avoided.
Horse: 0.1mg/kg, taken orally once a day. The dosage needs to be adjusted according to body weight and liver and kidney function.
Treatment and Monitoring
Short term treatment: Postoperative analgesia is usually administered continuously for 3 days, and can be extended to 5-7 days according to veterinary evaluation.
Long term treatment: Osteoarthritis requires continuous medication. It is recommended to monitor blood routine, biochemical indicators (ALT, ALP, BUN, Cr), and coagulation function (PT, APTT) every 3-6 months to be alert to liver and kidney dysfunction.
Dose adjustment: When the weight change exceeds 10%, the dose needs to be recalculated; Elderly dogs or patients with comorbidities are recommended to start with low doses.
Special populations and species differences
Young and elderly animals
Young animals: incomplete development of liver and kidney function, weak metabolism of NSAIDs, and prone to drug accumulation poisoning. It is recommended to start with a low dose (1mg/kg) and strengthen monitoring.
Elderly animals: often accompanied by complications such as liver and kidney diseases, cardiovascular diseases, etc., medication should be carefully evaluated for risks and benefits. It is recommended to start with low doses and monitor liver and kidney function every 2 weeks.
Pregnant and lactating animals
Pregnant animals: Ferocoxib can cross the placental barrier and potentially affect fetal development. In addition, NSAIDs can inhibit prostaglandin synthesis, leading to delayed or difficult delivery. Therefore, pregnant animals are prohibited from using fexorubicin.
Mammalian animals: The secretion of fexorubicin in breast milk is low, but it may have adverse effects on the offspring. It is recommended that breastfeeding animals avoid using it or stop using it after breastfeeding.
Current Status of Cat Applications
Although experimental studies have shown that fericoxib has good pharmacokinetic properties and anti-inflammatory effects in cats, there is currently no approved formulation for cat use. Cats are highly sensitive to NSAIDs and are prone to nephrotoxicity and gastrointestinal ulcers. Therefore, when cats use non Rocoxib drugs beyond the instructions, they need to be fully informed of the risks and closely monitored.
As a COX-2 selective inhibitor, firocoxib Injection has shown significant efficacy and good safety in the management of canine osteoarthritis and postoperative pain.It has become an important alternative to traditional NSAIDs by precisely inhibiting COX-2, reducing gastrointestinal and cardiovascular side effects. However, long-term medication still requires vigilance against liver and kidney function damage and gastrointestinal bleeding risks, and strict adherence to veterinary guidance for medication.Future research should focus on expanding indications, optimizing dosage forms, and deepening safety assessments to further enhance clinical application value. With the rapid development of the pet medical market and the increasing demand for high-quality drugs from consumers, non rocuronium injections are expected to play a more important role in animal pain management.
Drug Interactions and Compatibility Taboos
Effects of Metabolic Enzymes
Firocoxib tablets is mainly metabolized by the CYP450 enzyme system and CYP3A4, but its induction or inhibition effect is relatively weak. When used in combination with fluconazole (CYP2C9 inhibitor), the blood concentration of non fluconazole may increase by 50%, and the dosage needs to be adjusted to reduce it to 1mg/kg. In addition, when used in combination with CYP3A4 inducers (such as rifampicin), the metabolism of fexorubicin may accelerate, leading to a decrease in efficacy, and the dose needs to be increased to 3mg/kg.
Compatibility taboos
Combination use is prohibited: glucocorticoids (increasing ulcer risk), other NSAIDs (cumulative toxicity), anticoagulants (bleeding risk), and potentially nephrotoxic drugs (such as aminoglycosides).
Caution in combination: ACEIs (may lower blood pressure), diuretics (increases risk of nephrotoxicity), and digitalis drugs (may increase risk of arrhythmia).
Future research directions
Expanded Indications
Tumor related pain: In vitro studies have shown that fericoxib can inhibit tumor cell proliferation and induce apoptosis. In the future, animal experiments need to be conducted to verify its efficacy and safety in treating tumor pain in dogs and cats.
Neuropathic pain: The role of COX-2 in neuroinflammation provides a new target for treatment. Ferocoxib may alleviate neuropathic pain by inhibiting the activation of glial cells.
Formulation optimization
Controlled release formulations: Developing controlled release tablets or microspheres can prolong drug action time, reduce dosing frequency, and improve patient compliance.
Transdermal patch: Transdermal administration can avoid gastrointestinal irritation and first pass effects, and improve bioavailability. In the future, it is necessary to study the transdermal absorption mechanism and formulation process of fexorubicin.
Security reassessment
Long term toxicity study: Conduct long-term toxicity studies for more than 90 days to clarify the threshold and reversibility of liver and kidney function damage.
Drug concentration monitoring: Establish a blood drug concentration monitoring method for non rocuronium to guide individualized medication and reduce adverse reactions.
As a COX-2 selective inhibitor, firocoxib tablets have shown significant efficacy and good safety in the management of canine osteoarthritis and postoperative pain. It has become an important alternative to traditional NSAIDs by precisely inhibiting COX-2, reducing gastrointestinal and cardiovascular side effects. However, long-term medication still requires vigilance against liver and kidney function damage and gastrointestinal bleeding risks, and strict adherence to veterinary guidance for medication.
Hot Tags: firocoxib tablets, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, 7 chlorodibenzo c h acridine, 12H benzofuro 3 2 a carbazole, API Researching Only , Tetrahydrobiopterin BH4 Powder, Benz g indolo 2 3 b carbazole 7 9 dihydro 7 phenyl, Peptide